Scientific Literature

Apr 15, 2017

Prominent Oncogenic Roles of EVI1 in Breast Carcinoma

H. Wang, T. Schaefer, M. Konantz, M. Braun, Z. Varga, A. M. Paczulla, S. Reich, F. Jacob, S. Perner, H. Moch, T. N. Fehm, L. Kanz, K. Schulze-Osthoff, C. Lengerke , Cancer Research , DOI: 10.1158/0008-5472.CAN-16-0593
Overexpression of the EVI1 oncogene is associated typically with aggressive myeloid leukemia, but is also detectable in breast carcinoma where its contributions are unexplored. Analyzing a tissue microarray of 608 breast carcinoma patient specimens, we documented EVI1 overexpression in both estrogen receptor–positive (ER+) and estrogen receptor–negative (ER−) breast carcinomas. Here,...
Read More
Apr 5, 2017

Relevance of deep learning to facilitate the diagnosis of HER2 status in breast cancer

M. E. Vandenberghe, M. L. J. Scott, P. W. Scorer, M. Söderberg, D. Balcerzak, C. Barker , Scientific Reports , DOI: 10.1038/srep45938
Tissue biomarker scoring by pathologists is central to defining the appropriate therapy for patients with cancer. Yet, inter-pathologist variability in the interpretation of ambiguous cases can affect diagnostic accuracy. Modern artificial intelligence methods such as deep learning have the potential to supplement pathologist expertise to ensure constant diagnostic accuracy. We...
Read More
Apr 3, 2017

Matrix metalloproteinase processing of PTHrP yields a selective regulator of osteogenesis, PTHrP 1–17

J. S. Frieling, G. Shay, V. Izumi, S. T. Aherne, R. G. Saul, M. Budzevich, J. Koomen, C. C. Lynch , Oncogene , DOI: 10.1038/onc.2017.70
Parathyroid hormone-related protein (PTHrP) is a critical regulator of bone resorption and augments osteolysis in skeletal malignancies. Here we report that the mature PTHrP1–36 hormone is processed by matrix metalloproteinases to yield a stable product, PTHrP1–17. PTHrP1–17 retains the ability to signal through PTH1R to induce calcium flux and ERK...
Read More
Feb 14, 2017

Inhibition of proliferation and invasion in 2D and 3D models by 2-methoxyestradiol in human melanoma cells

R.R. Massaro, F. Faião-Flores, V.W. Rebecca, S. Sandri, D.K. Alves-Fernandes, P.C. Pennacchi, K.S.M. Smalley, S.S. Maria-Engler , Pharmacological Research , DOI: 10.1016/j.phrs.2017.02.013
Despite the recent advances in the clinical management of melanoma, there remains a need for new pharmacological approaches to treat this cancer. 2-methoxyestradiol (2ME) is a metabolite of estrogen that has shown anti-tumor effects in many cancer types. In this study we show that 2ME treatment leads to growth inhibition...
Read More
Feb 14, 2017

Inhibition of proliferation and invasion in 2D and 3D models by 2-methoxyestradiol in human melanoma cells

R.R. Massaro, F. Faião-Flores, V.W. Rebecca, S. Sandri, D.K. Alves-Fernandes, P.C. Pennacchi, K.S.M. Smalley, S.S. Maria-Engler , Pharmacological Research , DOI: 0.1016/j.phrs.2017.02.013
Despite the recent advances in the clinical management of melanoma, there remains a need for new pharmacological approaches to treat this cancer. 2-methoxyestradiol (2ME) is a metabolite of estrogen that has shown anti-tumor effects in many cancer types. In this study we show that 2ME treatment leads to growth inhibition...
Read More